GeneMatrix Inc. (KOSDAQ:109820)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,510.00
+10.00 (0.40%)
At close: Jan 29, 2026
-9.06%
Market Cap49.56B
Revenue (ttm)4.72B -3.7%
Net Income-2.09B
EPS-123.85
Shares Out20.39M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume105,468
Average Volume72,862
Open2,500.00
Previous Close2,500.00
Day's Range2,430.00 - 2,575.00
52-Week Range2,200.00 - 3,835.00
Beta1.19
RSI51.45
Earnings Daten/a

About GeneMatrix

GeneMatrix Inc. develops diagnostic products for various diseases in the field of molecular diagnostics. The company offers products for hepatitis B, hepatitis C, cervical cancer, sexually transmitted infections, respiratory infections, and gastrointestinal infections; vaccines for preventing various diseases; and new natural pharmaceutical materials for health enhancement and treatment. It also provides biochemical diagnostics, such as special chemistry and general chemistry, that includes semi and full auto analyer, and calibrators and contro... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances
Founded 2000
Employees 31
Stock Exchange KOSDAQ
Ticker Symbol 109820
Full Company Profile

Financial Performance

In 2018, GeneMatrix's revenue was 4.73 billion, a decrease of -8.75% compared to the previous year's 5.19 billion. Losses were -3.11 billion, 111.4% more than in 2017.

Financial Statements